Patients with Huntington’s disease, a fatal genetic illness that causes the breakdown of nerve cells in the brain, have up to 80 percent less cancer than the general population.
Northwestern Medicine scientists have discovered why Huntington’s is so toxic to cancer cells and harnessed it for a novel approach to treat cancer, a new study reports.
Huntington’s is caused by an over abundance of a certain type of repeating RNA sequences in one gene, huntingtin, present in every cell. The defect that causes the disease also is highly toxic to tumor cells. These repeating sequences — in the form of so-called small interfering RNAs — attack genes in the cell that are critical for survival. Nerve cells in the brain are vulnerable to this form of cell death, however, cancer cells appear to be much more susceptible.
“This molecule is a super assassin against all tumor cells,” said senior author Marcus Peter, the Tom D. Spies Professor of Cancer Metabolism at Northwestern University Feinberg School of Medicine. “We’ve never seen anything this powerful.”
Huntington’s disease deteriorates a person’s physical and mental abilities during their prime working years and has no cure.
The study will be published Feb. 12 in the journalĀ EMBO Reports.
To test the super assassin molecule in a treatment situation, Peter collaborated with Dr. Shad Thaxton, associate professor of urology at Feinberg, to deliver the molecule in nanoparticles to mice with human ovarian cancer. The treatment significantly reduced the tumor growth with no toxicity to the mice, Peter said. Importantly, the tumors did not develop resistance to this form of cancer treatment.
Peter and Thaxton are now refining the delivery method to increase its efficacy in reaching the tumor. The other challenge for the scientists is figuring out how to stabilize the nanoparticles, so they can be stored.
First and co-corresponding author Andrea Murmann, research assistant professor in medicine at Feinberg, also used the molecule to treat human and mouse ovarian, breast, prostate, liver, brain, lung, skin and colon cancer cell lines. The molecule killed all cancer cells in both species.
The Huntington’s cancer weapon was discovered by Murmann, who had worked with Peter on earlier research that identified an ancient kill-switch present in all cells that destroys cancer.
“I thought maybe there is a situation where this kill switch is overactive in certain people, and where it could cause loss of tissues,” Murmann said. “These patients would not only have a disease with an RNA component, but they also had to have less cancer.”
She started searching for diseases that have a lower rate of cancer and had a suspected contribution of RNA to disease pathology. Huntington’s was the most prominent.
When she looked at the repeating sequences in huntingtin, the gene that causes the disease, she saw a similar composition to the earlier kill switch Peter had found. Both were rich in the C and G nucleotides (molecules that form the building blocks of DNA and RNA).
“Toxicity goes together with C and G richness,” Murmann said. “Those similarities triggered our curiosity.”
In the case of people who have Huntington’s, the gene huntingtin has too many repeating sequences of the triplet sequence CAG. The longer the repeating sequence, the earlier they will develop the disease.
“We believe a short-term treatment cancer therapy for a few weeks might be possible, where we could treat a patient to kill the cancer cells without causing the neurological issues that Huntington’s patients suffer from,” Peter said.
Peter also is co-leader of the Translational Research in Solid Tumors Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Huntington’s patients have a lifetime exposure to these toxic RNA sequences, but generally don’t develop symptoms of the disease until age 40, he noted.
Every child of a parent with Huntington’s has 50/50 chance of carrying the faulty gene. Today, there are approximately 30,000 symptomatic Americans and more than 200,000 at-risk of inheriting the disease.
Learn more:Ā Huntington’s disease provides new cancer weapon
The Latest on: Cancer therapy
[google_news title=”” keyword=”Cancer therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cancer therapy
- Noninvasive liver cancer treatment now offered in Seattle's First Hill: HealthLinkon April 26, 2024 at 5:20 pm
The new treatment is called "Histotripsy" and uses ultrasound waves to target tumors and eliminates the need for patients to undergo surgery.
- Britain’s King Charles III will resume public duties next week after cancer treatment, palace sayson April 26, 2024 at 3:39 pm
Buckingham Palace says King Charles III will resume his public duties next week following treatment for cancer.
- Kurt Williams starts radiation treatment for prostate canceron April 26, 2024 at 3:08 pm
Today is the day! Today is the first day of my radiation treatment at Sentara's Oncology and Radiation department.
- King will resume public duties after positive cancer treatmenton April 26, 2024 at 12:39 pm
An external shot of Buckingham Palace after the King announces he plans to resume public duties after positive cancer treatment.
- King Charles to resume public duties after 'progress' in cancer treatmenton April 26, 2024 at 12:00 pm
Britain's King Charles III will resume public duties for the first time since his cancer diagnosis as Kate, the Princess of Wales, continues treatement.
- King Charles: What kind of cancer treatment is available to him - and what impact could it haveon April 26, 2024 at 11:30 am
The palace has said the King does not have prostate cancer and it is not yet clear what kind of cancer the King is suffering from or what kind of treatment he is having. However, there are three main ...
- King to resume public duties after positive cancer treatmenton April 26, 2024 at 11:10 am
King to resume public duties after positive cancer treatment - The monarch’s medical team is ‘greatly encouraged’ by progress made two months after his diagnosis ...
- King Charles III to return to public duties amid ongoing cancer treatmenton April 26, 2024 at 10:58 am
King Charles will resume engaging in public duties next week after nearly three months due to a cancer diagnosis.
- King Charles III to return to public duties amid cancer treatmenton April 26, 2024 at 10:46 am
King Charles III will return to public duties next week, a first since his cancer diagnosis was revealed publicly in February. Buckingham Palace announced Friday that Charles, 75, and his wife Queen ...
- King Charles announces return to public royal duties following his cancer treatment. Here's what to know about his health journey.on April 26, 2024 at 10:40 am
His Majesty The King will shortly return to public-facing duties after a period of treatment and recuperation following his recent cancer diagnosis. To help mark this milestone, The King and Queen ...
via Bing News